Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018

Publisher Name :
Date: 01-Oct-2018
No. of pages: 1000
Inquire Before Buying

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest preclinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2012 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

Chapter 5 provides a review of preclinical stage deal making since 2012. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2012, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2012.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2012.

In addition, a comprehensive appendix of all preclinical deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

Key benefits

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 provides the reader with the following key benefits:

In-depth understanding of preclinical stage deal trends since 2012

Access to headline, upfront, milestone and royalty data

Analysis of the structure of preclinical stage agreements with numerous real life case studies

Insight into the terms included in a preclinical stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 includes:

Trends in preclinical stage dealmaking in the biopharma industry since 2012

Analysis of preclinical stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life preclinical stage deals

Access to over 2,000 preclinical stage deals

The leading preclinical stage deals by value since 2012

Most active preclinical stage dealmakers since 2012

The leading preclinical stage partnering resources

In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides comprehensive access to available deals and contract documents for over 2,000 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?
2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals

Chapter 3 - Preclinical stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. - Tesaro
3.6.1.b. Case study : Marina Biotech - Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics - ThromboGenics
3.7.1.b. Case study: Pfizer - InSite Vision

Chapter 4 - Preclinical stage partnering payment strategies
4.1. Introduction
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in preclinical stage deal making
5.1. Introduction
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2012

Chapter 6 - Payment terms for preclinical stage partnering
6.1. Introduction
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates

Chapter 7 - Leading preclinical stage deals
7.1. Introduction
7.2. Top preclinical stage deals by value

Chapter 8 - Top 50 most active preclinical stage dealmakers
8.1. Introduction
8.2. Top 50 most active preclinical stage dealmakers

Chapter 9 - Preclinical stage partnering contracts directory
9.1. Introduction
9.2. Preclinical stage deals with contracts 2012 to 2018

Chapter 10 - Preclinical stage deal making by development stage
10.1. Introduction
10.2. Deals by preclinical stage

Appendices
Appendix 1 - Preclinical stage dealmaking by companies A-Z
Appendix 2 - Preclinical stage dealmaking by industry sector
Appendix 3 - Preclinical stage dealmaking by stage of development
Appendix 4 - Preclinical stage dealmaking by therapy area
Appendix 5 - Preclinical stage dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering

List of Tables and Figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2012- 2018), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for preclinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Preclinical stage partnering frequency since 2012
Figure 7: Preclinical stage partnering by deal type since 2012
Figure 8: Preclinical stage partnering by disease type since 2012
Figure 9: Preclinical stage partnering by technology type since 2012
Figure 10: Top 50 most active preclinical stage dealmakers since 2012
Figure 11: Review of upfront payments for preclinical stage deals
Figure 12: Review of milestone payments for preclinical stage deals
Figure 13: Review of royalty payments for preclinical stage deals
Figure 14: Preclinical stage deals with a headline value
Figure 15: Preclinical stage deals with an upfront value
Figure 16: Preclinical stage deals with a milestone value
Figure 17: Preclinical stage deals with a royalty rate value
Figure 18: Top preclinical stage deals by value since 2012
Figure 19: Most active preclinical stage dealmakers since 2012
  • Global Medical Cyclotron Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 16-Jan-2019        Price: US 3480 Onwards        Pages: 119
    Medical Cyclotron is a cyclotron that is a type of compact particle accelerator used to produce quantities of radioactive isotopes called positron emitters. Stable, non-radioactive isotopes are put into the cyclotron which accelerates charged particles to high energy in a magnetic field. The stable isotopes then react with a beam to form radioactive isotopes, which are then taken from the cyclotron, transformed into positron-emitting radiopharmaceuticals (PERs) within the facility's laboratories......
  • Global Orthopedic Medical Imaging Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jan-2019        Price: US 3480 Onwards        Pages: 120
    Orthopedic medical imaging allows doctors to non-invasively examine the internal structure of the body for aiding in diagnosing a medical condition. Medical imaging devices identify and monitor diseases or injuries by generating images representing internal anatomic structures of the patient's body. Orthopedic medical imaging has proved to be an informational tool that has helped physicians to diagnose the disease and response of the treatment. Orthopedic medical imaging deliver safe, effective,......
  • Global Photoacoustic Imaging Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jan-2019        Price: US 3480 Onwards        Pages: 120
    Photoacoustic imaging is a biomedical imaging technique that uses laser-generated ultrasound. Scope of the Report: This report focuses on the Photoacoustic Imaging in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The increasing number of non-communicable diseases to be one of the primary growth factors for the photoac......
  • Global Gamma Rays Collimators Market Insights, Forecast to 2025
    Published: 15-Jan-2019        Price: US 4900 Onwards        Pages: 112
    In X-ray optics, gamma ray optics, and neutron optics, a collimator is a device that filters a stream of rays so that only those traveling parallel to a specified direction are allowed through. The Gamma Rays Collimators market was valued at xx Million US$ in 2018 and is projected to reach xx Million US$ by 2025, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Gamm......
  • Global Preclinical Imaging Market Insights, Forecast to 2025
    Published: 11-Jan-2019        Price: US 4900 Onwards        Pages: 117
    Preclinical imaging is the visualization of living animals for research purposes, such as drug development. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes. Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. Broadly speaking, these imaging systems can be categorized into p......
  • Global and Chinese Gradient Power Amplifier Industry, 2018 Market Research Report
    Published: 11-Jan-2019        Price: US 3000 Onwards        Pages: 147
    The 'Global and Chinese Gradient Power Amplifier Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Gradient Power Amplifier industry with a focus on the Chinese market. The report provides key statistics on the market status of the Gradient Power Amplifier manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the i......
  • Global Mobile Medical Imaging Services Market Data Survey Report 2025
    Published: 11-Jan-2019        Price: US 1500 Onwards        Pages: 69
    Summary The global Mobile Medical Imaging Services market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing site......
  • Global Hybrid Imaging Market Size, Status and Forecast 2019-2025
    Published: 10-Jan-2019        Price: US 3900 Onwards        Pages: 97
    Hybrid imaging involves the fusion of two (or more) imaging techniques to form a new technique. By combining the innate advantages of the fused imaging technologies synergistically, a new and more powerful modality comes into being. Some of the hybrid imaging techniques includes Photon Emission Transmission (PET)/Computed Tomography (CT), ultrasound and Magnetic Resonance Imaging (MRI), ultrasound and CT, MRI and CT, and others. The hybrid imaging market has witnessed a growing adoption o......
  • Global Hybrid Imaging Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 10-Jan-2019        Price: US 3480 Onwards        Pages: 105
    Hybrid imaging involves the fusion of two (or more) imaging techniques to form a new technique. By combining the innate advantages of the fused imaging technologies synergistically, a new and more powerful modality comes into being. Some of the hybrid imaging techniques includes Photon Emission Transmission (PET)/Computed Tomography (CT), ultrasound and Magnetic Resonance Imaging (MRI), ultrasound and CT, MRI and CT, and others. Scope of the Report: This report studies the ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs